Sparkalis

Managing Director Filip Arnaut and Managing Partner Jean-Philippe Michaux lead the investment team, with Board President Daniel Malcorps providing governance oversight. The fund does not disclose whether it operates a formal investment committee, but its published structure shows the managing partner and managing director as the key decision-makers on capital deployment.

Sparkalis is the dedicated venture investment arm of Puratos Group, the Belgian B2B ingredients company. The fund is not legally separate in the way an independent GP would be; it leverages Puratos's global R&D, manufacturing footprint, and customer relationships across more than 100 countries to accelerate portfolio companies. This privileged relationship is the fund's central sourcing and scaling advantage.

Sparkalis describes its investment models as flexible and scalable, participating in seed, start-up, and growth stages. The firm has co-invested alongside other VCs in rounds like the €2M close by Time-Travelling Milkman in September 2025. There is no public data on whether Sparkalis consistently leads or follows, but its corporate-venture structure typically leans toward co-investment and consortium deals.

Sparkalis explicitly focuses on foodtech within health, well-being, and sustainability, with an emphasis on plant-based, gut health, fermentation, and traceability. There is no disclosed interest in therapeutics, general SaaS, or non-food biotech, so the fund likely screens out deals outside the intersection of food science and digital solutions for the food industry.

No. Sparkalis has not publicly disclosed a flagship fund size, AUM, or hard cap. The vehicle appears to operate on a deal-by-deal or balance-sheet capital allocation from Puratos Group rather than a closed-end fund structure raised from external limited partners.

The current portfolio includes companies in Belgium (THT, Cacaolab), the Netherlands (Time-Travelling Milkman, Fooditive), Germany (Bakerix), Austria (myBIOS), Switzerland (Food Brewer), Israel (Bountica), the US (CA Cultured), Nigeria (Baqers), and France (GF-Impact). The investment mandate is global, weighted toward European and Israeli foodtech startups.

Sparkalis has recorded at least one disclosed exit — LabID of Italy — which it labels a successful exit on its portfolio page. The firm does not publish a formal follow-on policy, but its commitment to early-stage science-heavy companies like cell-cultured cacao players suggests a willingness to support long technical runways rather than pursuing quick flips.